Eli Lilly bets on blood cancer drugs with $2.3B deal
Source ↗
👁 0
💬 0
Eli Lilly, a leading pharmaceutical company, has announced its plan to acquire Ajax Therapeutics for up to $2.3 billion in cash.
The acquisition is part of Eli Lilly's strategy to develop a new oral treatment for myelofibrosis, a rare and chronic blood cancer.
The clinical data for this innovative treatment is expected by 2026.
The acquisition is part of Eli Lilly's strategy to develop a new oral treatment for myelofibrosis, a rare and chronic blood cancer.
The clinical data for this innovative treatment is expected by 2026.
Comments (0)